Fundamental Analysis of TEMPEST THERAPEUTICS INC(NASDAQ:TPST) stock

Fundamental Rating

Taking everything into account, TPST scores 1 out of 10 in our fundamental rating. TPST was compared to 565 industry peers in the Biotechnology industry. TPST may be in some trouble as it scores bad on both profitability and health. TPST does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year TPST has reported negative net income.

In the past year TPST has reported a negative cash flow from operations.

In the past 5 years TPST always reported negative net income.

TPST had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

TPST has a worse Return On Assets (-75.30%) than 68.81% of its industry peers.

The Return On Equity of TPST (-187.45%) is worse than 68.09% of its industry peers.

		Industry Rank	Sector Rank
ROA	-75.3%
ROE	-187.45%
ROIC	N/A

ROA(3y)-57.76%

ROA(5y)-63.32%

ROE(3y)-128.62%

ROE(5y)-114.41%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TPST so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, TPST has more shares outstanding

Compared to 5 years ago, TPST has more shares outstanding

The debt/assets ratio for TPST has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -7.53, we must say that TPST is in the distress zone and has some risk of bankruptcy.

TPST has a worse Altman-Z score (-7.53) than 70.05% of its industry peers.

A Debt/Equity ratio of 0.12 indicates that TPST is not too dependend on debt financing.

TPST's Debt to Equity ratio of 0.12 is on the low side compared to the rest of the industry. TPST is outperformed by 65.60% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.12
Debt/FCF	N/A
Altman-Z	-7.53

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

TPST has a Current Ratio of 2.17. This indicates that TPST is financially healthy and has no problem in meeting its short term obligations.

TPST has a Current ratio of 2.17. This is in the lower half of the industry: TPST underperforms 74.15% of its industry peers.

TPST has a Quick Ratio of 2.17. This indicates that TPST is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of TPST (2.17) is worse than 72.91% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.17
Quick Ratio	2.17

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 31.09% over the past year.

EPS 1Y (TTM)31.09%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%22.22%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

TPST is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.06% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y21.49%

EPS Next 2Y13.01%

EPS Next 3Y5.01%

EPS Next 5Y2.06%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TPST. In the last year negative earnings were reported.

Also next year TPST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y13.01%

EPS Next 3Y5.01%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for TPST!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

TEMPEST THERAPEUTICS INC

NASDAQ:TPST (11/22/2024, 8:09:14 PM)

After market: 0.89 -0.02 (-1.71%)

0.9055

+0.01 (+1.33%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap22.83M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-75.3%
ROE	-187.45%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.12
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.17
Quick Ratio	2.17
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)31.09%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y21.49%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

TEMPEST THERAPEUTICS INC (TPST)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens